Medical Developments International Ltd – the next small-cap superstar?

Today's trading halt and Monday's announcement could signal the commencement of major upside for shareholders in Medical Developments International Ltd (ASX:MVP).

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Junior drug and respiratory equipment seller Medical Developments International Ltd (ASX: MVP) entered a trading halt today in advance of an announcement the company expects to make regarding its pending licensing application in Europe.

The What:

Up 96% so far for the year, Medical Development shares have soared on the back of a 300% increase in Earnings Before Interest, Tax, Depreciation, and Amortisation (EBITDA) compared to the previous year.

The company has already commenced selling its non-opioid analgesic Penthrox in Australia with some success, and is also very close to repaying the last of its outstanding debts, according to the most recent half-yearly report.

An anticipated update – which the company has hinted will be positive – on Monday should see Medical Development granted permission to license its products in key European markets.

So What?

The early stages of a company like this one are exciting as successful sales can trigger incredibly rapid profit and share price growth – as the recent tripling of EBITDA indicates.

Given that Europe is a far larger market than Australia, the potential for sales is significantly greater and as product awareness grows both domestically and overseas the company should enjoy rapid growth in its sales.

Now What?

I think investors can expect to see accelerating sales growth from Medical Development in the near to medium term, accompanied by a corresponding spike in its shares on Monday when the announcement is released.

Potentially the company could multiply its profits again this year and it will need to, considering that shares trade on an astronomical Price to Earnings (P/E) ratio of well over 100.

However, a strong financial position and no debt provide a solid footing, and if Medical Developments can double profit this year and again next year it will be trading on a P/E of under 20 (assuming share prices remain constant, which they won't).

Now you know why investors get excited about small-cap stocks!

Motley Fool contributor Sean O'Neill has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »